Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Animal models of cerebral ischaemia mimic at best less than 25% of all strokes. Compounds which prove efficacious in animal models should, therefore, only be expected to improve outcome in a quarter of all strokes. If trials for acute stroke are to succeed, stroke subgroups represented by the animal models should be targeted. For the other subgroups, e.g. lacunar stroke, appropriate animal models need to be developed. Moreover, thrombolysis should be included in animal models because it is likely to be used as a first line treatment for ischaemic stroke and any future therapeutics will need to be compatible with it.

Original publication




Journal article


Br Med Bull

Publication Date





307 - 317


Animals, Brain Ischemia, Clinical Trials as Topic, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Mice, Mice, Transgenic, Rats, Stroke